Literature DB >> 21674157

p63 expression in adamantinoma.

Brendan C Dickson1, Yair Gortzak, Robert S Bell, Peter C Ferguson, David J C Howarth, Jay S Wunder, Rita A Kandel.   

Abstract

Adamantinoma is a rare primary bone neoplasm with epithelial differentiation that is frequently associated with a concomitant fibrous component. Clinical, cytogenetic and histomorphologic overlap has previously been described with osteofibrous dysplasia, thereby suggesting a relationship between these two lesions. We performed a retrospective review of our archives to characterize the clinical and pathologic aspects of adamantinoma and osteofibrous dysplasia diagnosed at our institution, and to compare the expression patterns of p63 and keratin. Nine cases of adamantinoma (six classical, three osteofibrous dysplasia-like) and 11 cases of osteofibrous dysplasia were identified. The epithelial component in adamantinoma was found to stain for p63. Rare cells expressing p63 were also identified in eight cases of osteofibrous dysplasia. Expression of p63 was not identified in any of the five cases of fibrous dysplasia controls. The presence of staining for p63, albeit rare, in osteofibrous dysplasia supports the notion of a possible relationship between osteofibrous dysplasia and adamantinoma. Furthermore, our results suggest that, in some situations, p63 may be useful in helping differentiate metastatic carcinoma from adamantinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674157     DOI: 10.1007/s00428-011-1101-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  44 in total

1.  Ewing's sarcoma of the soft tissues? Case report.

Authors:  F Bertoni; M Campanacci
Journal:  Ital J Orthop Traumatol       Date:  1976-12

2.  p63 is a p53 homologue required for limb and epidermal morphogenesis.

Authors:  A A Mills; B Zheng; X J Wang; H Vogel; D R Roop; A Bradley
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

Review 3.  p63 and p73, the ancestors of p53.

Authors:  V Dötsch; F Bernassola; D Coutandin; E Candi; G Melino
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-19       Impact factor: 10.005

4.  Adamantinoma of the long bones. The experience at the Istituto Ortopedico Rizzoli.

Authors:  M Campanacci; A Giunti; F Bertoni; M Laus; S Gitelis
Journal:  Am J Surg Pathol       Date:  1981-09       Impact factor: 6.394

Review 5.  P63 and P73: P53 mimics, menaces and more.

Authors:  A Yang; F McKeon
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

6.  Morphologic diversity of long bone adamantinoma. The concept of differentiated (regressing) adamantinoma and its relationship to osteofibrous dysplasia.

Authors:  B Czerniak; R R Rojas-Corona; H D Dorfman
Journal:  Cancer       Date:  1989-12-01       Impact factor: 6.860

7.  Expression of p63 and p73 in ameloblastomas.

Authors:  Hiroyuki Kumamoto; Kousuke Ohki; Kiyoshi Ooya
Journal:  J Oral Pathol Med       Date:  2005-04       Impact factor: 4.253

8.  Human bone marrow-derived mesenchymal stem cells differentiate into epidermal-like cells in vitro.

Authors:  Han Chun-mao; Wang Su-yi; Lai Ping-ping; Cen Hang-hui
Journal:  Differentiation       Date:  2007-02-05       Impact factor: 3.880

9.  Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis.

Authors:  H M Hazelbag; G J Fleuren; L J vd Broek; A H Taminiau; P C Hogendoorn
Journal:  Am J Surg Pathol       Date:  1993-12       Impact factor: 6.394

10.  Adamantinoma of bone. An electron microscopic and immunohistochemical study.

Authors:  R H Knapp; M R Wick; B W Scheithauer; K K Unni
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1982
View more
  1 in total

1.  Diagnostic pitfalls in tibial adamantinoma: two cases with a clinicopathological review.

Authors:  Mehala Tharmabala; Vijayananda Kandapur; Jenna-Lynn Senger; Rani Kanthan
Journal:  Clin Pract       Date:  2011-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.